Supplementary Online Content

McDowell K, Kondo T, Talebi A, et al. Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. *JAMA Cardiol*. Published online March 27, 2024. doi:10.1001/jamacardio.2024.0284

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplementary Table 1: Baseline Characteristics and treatment by endpoint in DELIVER derivation cohort

	HFH/CV death		CV death		All cause mortality	
	Without event	With event	Without event	With event	Without event	With event
	N=5,211	N=1,052	N=5,771	N=492	N=5,240	N=1,023
Randomized to dapagliflozin	2,656 (51.0)	475 (45.2)	2,900 (50.3)	231 (47.0)	2,634 (50.3)	497 (48.6)
Age, yr	71.5±9.5	72.3±9.8	71.5±9.5	73.1±9.9	71.2±9.5	74.1±9.5
Male-no. (%)	2,869 (55.1)	647 (61.5)	3,205 (55.5)	311 (63.2)	2,873 (54.8)	643 (62.9)
Race-no. (%)						
White	3,660 (70.2)	779 (74.0)	4,066 (70.5)	373 (75.8)	3,661 (69.9)	778 (76.1)
Black	124 (2.4)	35 (3.3)	145 (2.5)	14 (2.8)	133 (2.5)	26 (2.5)
Asian	1,082 (20.8)	192 (18.3)	1,207 (20.9)	67 (13.6)	1,139 (21.7)	135 (13.2)
Other	345 (6.6)	46 (4.4)	353 (6.1)	38 (7.7)	307 (5.9)	84 (8.2)
Region- no. (%)						
Europe	2,477 (47.5)	528 (50.2)	2,748 (47.6)	257 (52.2)	2,472 (47.2)	533 (52.1)
Asia	1,042 (20.0)	184 (17.5)	1,162 (20.1)	64 (13.0)	1,100 (21.0)	126 (12.3)
North America	662 (12.7)	189 (18.0)	779 (13.5)	72 (14.6)	711 (13.6)	140 (13.7)

Latin America	1,030 (19.8)	151 (14.4)	1,082 (18.7)	99 (20.1)	957 (18.3)	224 (21.9)
Body Mass Index-kg/m^2	29.8±6.0	30.1±6.5	29.9±6.1	29.2±6.3	29.9±6.1	29.5±6.2
Recent heart failure hospitalization- no.(%)	696 (13.4)	306 (29.1)	857 (14.9)	145 (29.5)	763 (14.6)	239 (23.4)
Prior heart failure hospitalization-no. (%)	1,956 (37.5)	583 (55.4)	2,270 (39.3)	269 (54.7)	2,031 (38.8)	508 (49.7)
Smoker-no.(%)	2,227 (42.7)	518 (49.2)	2,500 (43.3)	245 (49.8)	2,271 (43.3)	474 (46.3)
Left ventricular ejection fraction- %	4.0±4.8	4.6±5.0	4.0±4.8	5.1±5.0	4.0±4.8	4.6±4.9
NYHA functional classification-no.(%)						
I	0 (0.0)	1 (0.1)	1 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)
II	4,023 (77.2)	690 (65.6)	4,394 (76.1)	319 (64.8)	4,030 (76.9)	683 (66.8)
III	1,179 (22.6)	352 (33.5)	1,360 (23.6)	171 (34.8)	1,197 (22.8)	334 (32.6)
IV	9 (0.2)	9 (0.9)	16 (0.3)	2 (0.4)	12 (0.2)	6 (0.6)
Pulse-beats/min	71.2±11.7	72.9±11.9	71.4±11.7	72.1±11.7	71.4±11.8	72.0±11.6
Systolic blood pressure-mmHg	128.3±15.2	127.9±16.1	128.4±15.3	126.6±15.3	128.4±15.3	127.4±15.7
Heart failure duration more than 1year-no. (%)	3,481 (66.9)	775 (73.7)	3,894 (67.5)	362 (73.6)	3,515 (67.1)	741 (72.5)
Asthma-no.(%)	310 (6.0)	80 (7.6)	361 (6.3)	29 (5.9)	332 (6.3)	58 (5.7)
Chronic Obstructive Pulmonary Disease-no.(%)	516 (9.9)	176 (16.7)	605 (10.5)	87 (17.7)	544 (10.4)	148 (14.5)

Type 2 Diabetes Mellitus-no.(%)	2,260 (43.4)	546 (51.9)	2,568 (44.5)	238 (48.4)	2,306 (44.0)	500 (48.9)
Angina Pectoris-no.(%)	1,239 (23.8)	258 (24.5)	1,369 (23.7)	128 (26.0)	1,224 (23.4)	273 (26.7)
Myocardial Infarction-no.(%)	1,326 (25.4)	313 (29.8)	1,480 (25.6)	159 (32.3)	1,332 (25.4)	307 (30.0)
Coronary Artery Bypass Graft-no.(%)	589 (11.3)	162 (15.4)	685 (11.9)	66 (13.4)	606 (11.6)	145 (14.2)
Atrial Fibrillation-no.(%)	2,827 (54.3)	638 (60.6)	3,186 (55.2)	279 (56.7)	2,876 (54.9)	589 (57.6)
Hypertension-no.(%)	4,599 (88.3)	954 (90.7)	5,106 (88.5)	447 (90.9)	4,629 (88.3)	924 (90.3)
TIA/Stroke-no.(%)	596 (11.4)	176 (16.7)	681 (11.8)	91 (18.5)	603 (11.5)	169 (16.5)
Peripheral arterial disease-no.(%)	2,205 (42.3)	492 (46.8)	2,465 (42.7)	232 (47.2)	2,211 (42.2)	486 (47.5)
Pacemaker insertion-no.(%)	600 (11.5)	157 (14.9)	681 (11.8)	76 (15.4)	605 (11.5)	152 (14.9)
Chronic Kidney Disease-no.(%)	1,383 (26.5)	383 (36.4)	1,599 (27.7)	167 (33.9)	1,404 (26.8)	362 (35.4)
Malignant Neoplasm -no.(%)	239 (4.6)	65 (6.2)	284 (4.9)	20 (4.1)	247 (4.7)	57 (5.6)
Mineralocorticoid receptor antagonist-no.(%)	2,216 (42.5)	451 (42.9)	2,438 (42.3)	229 (46.5)	2,213 (42.2)	454 (44.4)
Sacubitril/Valsartan -no.(%)	240 (4.6)	61 (5.8)	280 (4.9)	21 (4.3)	251 (4.8)	50 (4.9)
Diuretics-no.(%)	5,094 (97.8)	1,029 (97.9)	5,640 (97.8)	483 (98.2)	5,118 (97.7)	1,005 (98.2)

Data are presented as mean±SD for continuous measures, and n (%) for categorical measures.

Abbreviations: CV, Cardiovascular; HFH, heart failure hospitalisation; NYHA, New York Heart Association; TIA, transient ischaemic attack.

Supplementary Table 2: Event rate per 100 person-years for each risk quintile at 2 years

Quintile Risk	No of Events	Crude rate per 100 person-years
HFH/CV death		
1	65	2.27 (1.78-2.91)
2	84	2.98 (2.41-3.69)
3	141	5.16 (4.37-6.08)
4	218	8.54 (7.48-9.78)
5	385	17.3 (15.7-19.2)
CV death		
1	35	1.21 (0.87-1.69)
2	34	1.17 (0.84-1.64)
3	55	1.90 (1.46-2.47)
4	80	2.86 (2.29-3.56)
5	183	7.14 (6.18-8.25)
All cause death		
1	62	2.08 (1.62-2.67)
2	97	3.33 (2.73-4.07)
3	131	4.58 (3.86-5.43)
4	171	6.11 (5.26-7.10)
5	328	13.0 (11.68-14.50)

Supplementary Table 3: PREDICT-HFpEF model for the outcome of heart failure hospitalization (HFH).

Variable	Hazard Ratio	Chi-square	Coefficient	P value
NTproBNP (per log unit increase)	1.57(1.44-1.71)	10.3	0.445	<0.001
HFH last 6 months	1.83 (1.51-2.21)	6.22	0.603	<0.001
North America	1.75(1.45-2.12)	5.86	0.562	<0.001
Creatinine (per 5)	1.03(1.44-1.04)	5.17	0.029	<0.001
ARNI therapy	2.07(1.52-2.81)	4.66	0.726	<0.001
HFH (any previous)	1.44(1.19-1.73)	4.10	0.369	<0.001
Not receiving dapagliflozin	1.34(1.16-1.55)	4.00	0.296	<0.001
History of coronary artery disease	1.44(1.19-1.76)	3.69	0.368	<0.001
Heart rate (per 10 bpm increase)	1.11(1.04-1.17)	3.37	0.110	0.001
Interaction term				
On ARNI from North America	0.25 (0.10-0.63)	-2.92	-1.407	0.004

Supplementary Table 4: Performance of model for heart failure hospitalization in derivation (DELIVER) and validation (PARAGON-HF) cohort by Harrell's C statistic

	DELIVER	PARAGON-HF
	C statistic (95% CI)	C statistic (95% CI)
Overall	0.72(0.70-0.74)	0.66(0.64-0.67)
1 year	0.74(0.72-0.77)	0.71(0.68-0.74)
2 years	0.73(0.71-0.75)	0.66(0.64-0.68)

Supplementary Table 5: Model performance with and without HF Hospitalization within last 6 months assessed by Harrell's C statistic

	(1) C statistic (95% CI) for HFH within last 6 months alone	(2) C statistic (95% CI) for baseline model without HFH within last 6 months	(3) C statistic (95% CI) for baseline model with HFH within last 6 months	Difference in C-statistic (95% CI), p-value (2) versus (1)	Difference in C-statistic (95% CI), p-value (3) versus (1)
HFH/CV death					
1 year	0.59 (0.58-0.62)	0.72 (0.70-0.74)	0.73 (0.71-0.75)	0.13 (0.09-0.15) P <0.001	0.14 (0.11-0.15) P <0.001
2 years	0.58 (0.56-0.60)	0.70 (0.68-0.72)	0.71 (0.69-0.73)	0.12 (0.10-0.14) P <0.001	0.13 (0.11-0.14) P <0.001
CV death					
1 year	0.60 (0.57-0.63)	0.73 (0.69-0.77)	0.75 (0.71-0.79)	0.13 (0.09-0.18)	0.14 (0.11-0.19)

				P <0.001	P <0.001
2 years	0.58 (0.66-0.60)	0.70 (0.67-0.72)	0.71 (0.68-0.74)	0.12 (0.08-0.15) P <0.001	0.13 (0.11-0.14) P <0.001
All cause death					
1 year	0.57 (0.54-0.59)	0.70 (0.67-0.63)	0.71 (0.68-0.74)	0.13 (0.10-0.16) P <0.001	0.14 (0.10-0.16) P <0.001
2 years	0.55 (0.54-0.57)	0.68 (0.66-0.70)	0.68 (0.66-0.70)	0.13 (0.11-0.15) P<0.001	0.13 (0.11-0.15) P <0.001

Suppplementary Table 6: Reclassification of base model with addition of NTproBNP and HF Hospitalization within last 6 months

	Addition of NTproBNP to model		Addition of HF Hospitalization within 6 months to model	
	IDI (95% CI)	NRI (95% CI)	IDI (95% CI)	NRI (95% CI)
HFH/CV death				
1 year	0.022 (0.012-0.033) P <0.001	0.177 (0.135-0.225) P<0.001	0.011 (0.004-0.019) P <0.001	0.059 (0.006-0.112) P<0.02
2 years	0.023 (0.014-0.036) P<0.001	0.190 (0.150-0.239) P <0.001	0.012 (0.006-0.019) P <0.001	0.055 (0.005-0.098) P<0.03)
CV death				
1 year	0.021 (0.010-0.043) P <0.001	0.214 (0.125-0.295) P <0.001	0.090 (0.003-0.022) P 0.007	0.204 (0.123-0.272) P <0.001
2 years	0.019 (0.010-0.033)	0.160 (0.004-0.017)	0.011 (0.004-0.021)	0.164 (0.122-0.210)

	P <0.001)	P <0.001)	P <0.001	P <0.001
All cause death				
1 year	0.023	0.181	0.003	-0.021
	(0.013-0.040)	(0.122-0.236)	(0.0-0.008)	(-0.075-0.041)
	P <0.001	P<0.001	P <0.02	P 0.645
2 years	0.022	0.130	0.004	-0.016
	(0.014-0.035)	(0.088-0.174)	(0.00.1-0.008)	(-0.054-0.035)
	P <0.001	P <0.001	P <0.001	P 0.61

Supplementary Table 7: List of Candidate Variables and extent of missing data: DELIVER

	Missing-no. (%)
Dapagliflozin	0
Age	0
Male	0
Race	0
Region	0
Body mass index	0
Recent heart failure hospitalisation	0
Previous heart failure hospitalisation	0
Smoker	0
Left ventricular ejection fraction	0
NYHA functional classification	0
Heart rate	0
Systolic blood pressure	0

Heart failure duration	0
Asthma	2 (0.03)
Chronic obstructive pulmonary disease	2 (0.03)
Diabetes	0
Angina	0
Myocardial infarction	0
Coronary artery bypass graft	0
Hypertension	0
Atrial fibrillation	0
Peripheral arterial disease	0
Transient ischaemic attack/Stroke	0
Malignancy	0
Pacemaker	0
Chronic kidney disease	0
Mineralocorticoid receptor antagonist	2 (0.03)
Sacubitril/Valsartan	2 (0.03)

Diuretic	2 (0.03)
Creatinine	1 (0.015)
NTproBNP	1 (0.015)

Supplementary Table 8: Baseline Characteristics and treatment by endpoint in PARAGON-HF validation cohort

	HFH/CV death		CV death		All cause mortality	
	Without event	**With event**	**Without event**	**With event**	**Without event**	**With event**
	N=3,713	**N=1,083**	**N= 4,380**	**N= 416**	**N= 4,105**	**N = 691**
Age- yrs	72.4±8.3	74.1±8.6	72.5±8.4	75.0±8.3	72.3±8.4	75.4±8.2
Male- no. (%)	1,758 (47.3)	559 (51.6)	2,086 (47.6)	231 (55.5)	1,938 (47.2)	379 (54.8)
Race- no (%)						
White	3,035 (81.7)	872 (80.5)	3,574 (81.6)	333 (80.0)	3,338 (81.3)	569 (82.3)
Black	68 (1.8)	34 (3.1)	94 (2.1)	8 (1.9)	91 (2.2)	11 (1.6)
Asian	456 (12.3)	151 (13.9)	544 (12.4)	63 (15.1)	518 (12.6)	89 (12.9)
Other	154 (4.1)	26 (2.4)	168 (3.8)	12 (2.9)	158 (3.8)	22 (3.1)
Region- no. (%)						
Europe	2476 (66.6)	629 (58.0)	2857 (59.1)	248 (59.6)	2669 (65.0)	315(45.5)
Asia	568 (15.3)	194 (17.9)	683 (15.6)	79 (19.0)	647 (15.8)	115 (16.6)
North America	358 (9.6)	201 (18.6)	498 (11.4)	61 (14.7)	469 (11.4)	90 (13.0)
Latin America	311 (8.4)	59 (5.4)	342 (7.8)	28 (6.7)	320 (7.8)	50 (7.2)

Body Mass Index- kg/m2	30.2±4.9	30.4±5.2	30.3±5.0	29.5±4.9	30.3±5.0	29.6±5.0
Recent heart failure hospitalization- no.(%)	1,111 (29.9)	509 (47.0)	1,446 (33.0)	174 (41.8)	1,345 (32.8)	275 (39.8)
Prior heart failure hospitalization-no. (%)	1,621 (43.7)	685 (63.3)	2,067 (47.2)	239 (57.5)	1,922 (46.8)	384 (55.6)
Smoker-no.(%)	276 (7.5)	77 (7.2)	322 (7.4)	31 (7.5)	306 (7.5)	47 (6.9)
Left ventricular ejection fraction- %	31.2±7.9	32.3±7.8	31.3±7.9	33.3±7.7	31.3±7.9	32.6±7.8
NYHA functional classification-no.(%)						
I	107 (2.9)	30 (2.8)	128 (2.9)	9 (2.2)	124 (3.0)	13 (1.9)
II	2,925 (78.8)	781 (72.2)	3,406 (77.8)	300 (72.1)	3,206 (78.1)	500 (72.4)
III	669 (18.0)	263 (24.3)	831 (19.0)	101 (24.3)	761 (18.5)	171 (24.7)
IV	11 (0.3)	8 (0.7)	13 (0.3)	6 (1.4)	12 (0.3)	7 (1.0)
Pulse-beats/min	70.0±12.1	71.8±12.7	70.2±12.2	72.7±12.7	70.1±12.1	72.6±12.8
Systolic blood pressure-mmHg	130.4±15.1	131.1±16.6	130.6±15.4	130.2±16.4	130.7±15.3	129.9±16.5
Heart failure duration more than 1year-no. (%)	2,117 (57.1)	692 (64.1)	2,553 (58.4)	256 (61.5)	2,380 (58.1)	429 (62.1)
Asthma-no.(%)	262 (7.1)	86 (7.9)	320 (7.3)	28 (6.7)	303 (7.4)	45 (6.5)
Chronic Obstructive Pulmonary Disease-no.(%)	441 (11.9)	229 (21.1)	585 (13.4)	85 (20.4)	525 (12.8)	145 (21.0)
Type 2 Diabetes Mellitus-no.(%)	1,511 (40.7)	551 (50.9)	1,851 (42.3)	211 (50.7)	1,702 (41.5)	360 (52.1)

Angina Pectoris-no.(%)	1,029 (27.7)	359 (33.1)	1,246 (28.4)	142 (34.1)	1,170 (28.5)	218 (31.5)
Myocardial Infarction-no.(%)	787 (21.2)	296 (27.3)	952 (21.7)	131 (31.5)	891 (21.7)	192 (27.8)
Coronary Artery Bypass Graft-no.(%)	397 (10.7)	173 (16.0)	498 (11.4)	72 (17.3)	461 (11.2)	109 (15.8)
Atrial Fibrillation-no.(%)	1,064 (28.7)	339 (31.3)	1,266 (28.9)	137 (32.9)	1,153 (28.1)	250 (36.2)
Hypertension-no.(%)	3,544 (95.4)	1,040 (96.0)	4,185 (95.5)	399 (95.9)	3,920 (95.5)	664 (96.1)
TIA/Stroke- no. (%)	491 (13.2)	191 (17.6)	588 (13.4)	94 (22.6)	551 (13.4)	131 (19.0)
Peripheral arterial disease-no.(%)	291 (7.8)	115 (10.6)	356 (8.1)	50 (12.0)	326 (7.9)	80 (11.6)
Pacemaker insertion-no.(%)	344 (9.3)	115 (10.6)	427 (9.7)	32 (7.7)	386 (9.4)	73 (10.6)
Malignant Neoplasm -no.(%)	336 (9.1)	97 (9.0)	401 (9.2)	32 (7.7)	369 (9.0)	64 (9.3)
Mineralocorticoid receptor antagonist-no.(%)	917 (24.7)	322 (29.7)	1,118 (25.5)	121 (29.1)	1,051 (25.6)	188 (27.2)
Sacubitril/Valsartan -no.(%)	1,881 (50.7)	526 (48.6)	2,203 (50.3)	204 (49.0)	2,065 (50.3)	342 (49.5)
Diuretics-no.(%)	3,540 (95.3)	1,045 (96.5)	4,188 (95.6)	397 (95.4)	3,916 (95.4)	669 (96.8)

Data are presented as mean±SD for continuous measures, and n (%) for categorical measures.

Abbreviations: CV, Cardiovascular; HFH, heart failure hospitalisation; NYHA, New York Heart Association; TIA, transient ischaemic attack.

Supplementary Table 9: Baseline Characteristics and treatment by endpoint in I-Preserve validation cohort

	HFH/CV death		CV death		All cause mortality	
	Without event N=3,075	With event N=1,053	Without event N= 3,515	With event N=613	Without event N =3,247	With event N=881
Age- yrs	70.8±6.7	74.0±7.2	71.2±6.8	74.1±7.4	70.9±6.6	74.5±7.5
Male-no (%)	1,168 (38.0)	469 (44.5)	1,341 (38.2)	296 (48.3)	1,203 (37.0)	434 (49.3)
Race-no (%)						
White	2,859 (93.0)	1,000 (95.0)	3,281 (93.3)	578 (94.3)	3,036 (93.5)	823 (93.4)
Black	55 (1.8)	27 (2.6)	65 (1.8)	17 (2.8)	56 (1.7)	26 (3.0)
Asian	31 (1.0)	3 (0.3)	32 (0.9)	2 (0.3)	30 (0.9)	4 (0.5)
Other	130 (4.2)	23 (2.2)	137 (3.9)	16 (2.6)	125 (3.8)	28 (3.2)
Region-no (%)						
Europe	2204 (71.7)	734 (69.7)	2497 (71.0)	442 (72.1)	2323 (71.5)	616 (70.0)
Asia	67 (2.2)	21 (0.2)	76 (2.2)	12 (2.0)	66 (2.0)	22 (2.5)
North America	246 (8.0)	139 (13.2)	316 (9.0)	69 (11.3)	282 (8.7)	103 (11.7)

Latin America	558 (18.1)	158 (15.0)	626 (17.8)	90 (14.7)	576 (17.7)	140 (15.9)
Body Mass Index kg/m^2	29.6±5.1	29.6±5.8	29.7±5.2	29.1±5.8	29.8±5.1	29.1±5.7
Recent heart failure hospitalization-no.(%)	1,165 (37.9)	651 (61.8)	1,461 (41.6)	355 (57.9)	1,323 (40.7)	493 (56.0)
Left ventricular ejection fraction- %	60.1±9.1	57.6±9.2	59.9±9.1	57.0±9.3	59.9±9.0	57.6±9.6
NYHA functional classification-no.(%)						
I	1 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)	1 (0.0)	0 (0.0)
II	612 (19.9)	258 (24.5)	740 (21.1)	130 (21.2)	683 (21.0)	187 (21.2)
III	2,403 (78.2)	741 (70.4)	2,697 (76.8)	447 (72.9)	2,495 (76.9)	649 (73.7)
IV	58 (1.9)	54 (5.1)	76 (2.2)	36 (5.9)	67 (2.1)	45 (5.1)
Pulse-beats/min	70.8±10.2	73.4±11.0	71.0±10.2	73.8±11.3	70.9±10.1	73.5±11.4
Systolic blood pressure-mmHg	136.5±14.6	135.8±16.2	136.5±14.6	135.6±16.9	136.6±14.5	135.6±16.8
Heart failure duration more than 1year-no. (%)	1,493 (48.6)	504 (47.9)	1,732 (49.3)	265 (43.2)	1,589 (48.9)	408 (46.3)
Asthma-no.(%)	242 (7.9)	149 (14.2)	313 (8.9)	78 (12.7)	270 (8.3)	121 (13.7)

Chronic Obstructive Pulmonary Disease-no.(%)	743 (24.2)	391 (37.1)	914 (26.0)	220 (35.9)	820 (25.3)	314 (35.6)
Type 2 Diabetes Mellitus-no.(%)	1,215 (39.5)	437 (41.5)	1,386 (39.4)	266 (43.4)	1,303 (40.1)	349 (39.6)
Myocardial Infarction-no.(%)	668 (21.7)	301 (28.6)	770 (21.9)	199 (32.5)	702 (21.6)	267 (30.3)
Coronary Artery Bypass Graft-no.(%)	381 (12.4)	167 (15.9)	457 (13.0)	91 (14.8)	413 (12.7)	135 (15.3)
Atrial Fibrillation-no.(%)	746 (24.3)	463 (44.0)	955 (27.2)	254 (41.4)	850 (26.2)	359 (40.7)
Hypertension-no.(%)	2,733 (88.9)	917 (87.1)	3,124 (88.9)	526 (85.8)	2,897 (89.2)	753 (85.5)
TIA/Stroke- no. (%)	261 (8.5)	138 (13.1)	308 (8.8)	91 (14.8)	273 (8.4)	126 (14.3)
Pacemaker insertion-no.(%)	141 (4.6)	111 (10.5)	195 (5.5)	57 (9.3)	170 (5.2)	82 (9.3)
Mineralocorticoid receptor antagonist-no.(%)	378 (12.7)	243 (23.8)	481 (14.2)	140 (23.4)	421 (13.4)	200 (23.4)
Diuretics-no.(%)	2,401 (80.9)	922 (90.3)	2,786 (82.1)	537 (89.8)	2,568 (81.9)	755 (88.3)

Data are presented as mean±SD for continuous measures, and n (%) for categorical measures.

Supplementary Table 10: Extent of missing data: PARAGON HF and I-Preserve

	Missing-no. (%)	
	PARAGON-HF	I-Preserve
NTproBNP	39 (0.8)	648 (15.7)
Recent heart failure hospitalisation	0	0
Creatinine	1 (0.02)	90 (2.2)
Transient ischaemic attack/Stroke	0	0
Dapagliflozin	0	0
Chronic obstructive pulmonary disease	0	0
Previous heart failure hospitalisation	0	*2312
Diabetes	0	0
Age	0	0
Region: (N America)	0	0
Heart failure duration greater than 1 year	12 (0.3)	0
Heart rate	1 (0.02)	4 (0.09)
Body mass index	2 (0.04)	19 (0.46)
Region: Asia	0	0
Left ventricular ejection fraction	0	3 (0.07)
Region: Latin America	0	0
Male	0	0
NYHA functional classification	2 (0.04)	1 (0.02)

*Data only available for heart failure hospitalisation in last 6 months